APA (7th ed.) Citation

Khunti, K., Ruan, Y., Davies, J., Field, B. C., Harris, S., Kosiborod, M., . . . Ryder, R. (2022). Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19. Diabetes Care, 45(12), 2838. https://doi.org/10.2337/dc22-0357

Chicago Style (17th ed.) Citation

Khunti, Kamlesh, et al. "Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19." Diabetes Care 45, no. 12 (2022): 2838. https://doi.org/10.2337/dc22-0357.

MLA (9th ed.) Citation

Khunti, Kamlesh, et al. "Association Between SGLT2 Inhibitor Treatment and Diabetic Ketoacidosis and Mortality in People With Type 2 Diabetes Admitted to Hospital With COVID-19." Diabetes Care, vol. 45, no. 12, 2022, p. 2838, https://doi.org/10.2337/dc22-0357.